

Dong Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1258212/publications.pdf>

Version: 2024-02-01

72
papers

974
citations

516710

16
h-index

477307

29
g-index

73
all docs

73
docs citations

73
times ranked

1943
citing authors

#	ARTICLE	IF	CITATIONS
1	Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 15.	6.2	101
2	York platelet syndrome is a CRAC channelopathy due to gain-of-function mutations in STIM1. <i>Molecular Genetics and Metabolism</i> , 2015, 114, 474-482.	1.1	94
3	Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 806-816.	0.6	61
4	Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. <i>American Journal of Hematology</i> , 2016, 91, 888-893.	4.1	60
5	Lysosomal Storage and Albinism Due to Effects of a De Novo CLCN7 Variant on Lysosomal Acidification. <i>American Journal of Human Genetics</i> , 2019, 104, 1127-1138.	6.2	59
6	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1189-1211.	3.0	55
7	STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. <i>Human Pathology</i> , 2018, 73, 74-81.	2.0	49
8	Indexes of von Willebrand Factor as Biomarkers of Aortic Stenosis Severity (from the Biomarkers of Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	45
9	A prospective, blinded study of a PF4-dependent assay for HIT diagnosis. <i>Blood</i> , 2021, 137, 1082-1089.	1.4	28
10	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. <i>Leukemia</i> , 2020, 34, 2519-2524.	7.2	25
11	Clinicopathologic Features of CDK6 Translocation-associated B-cell Lymphoproliferative Disorders. <i>American Journal of Surgical Pathology</i> , 2009, 33, 720-729.	3.7	24
12	Combined alpha-delta platelet storage pool deficiency is associated with mutations in GFI1B. <i>Molecular Genetics and Metabolism</i> , 2017, 120, 288-294.	1.1	22
13	Local Verification and Assignment of Mean Normal Prothrombin Time and International Sensitivity Index Values across Various Instruments: Recent Experience and Outcome from North America. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 115-120.	2.7	20
14	BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. <i>Cancer Genetics</i> , 2016, 209, 223-228.	0.4	19
15	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1170-1179.	4.1	19
16	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021, 96, 1450-1460.	4.1	19
17	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. <i>Modern Pathology</i> , 2020, 33, 334-343.	5.5	18
18	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (la-CBF) Tj ETQq0 0 0 rgBT /Overlock 17	2.8	17

#	ARTICLE	IF	CITATIONS
19	Usefulness of Von Willebrand Factor Activity Indexes to Predict Therapeutic Response in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 117, 436-442.	1.6	16
20	The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. <i>Blood Cancer Journal</i> , 2020, 10, 7.	6.2	14
21	From Vitamin K Antagonists to Liver International Normalized Ratio: A Historical Journey and Critical Perspective. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 845-851.	2.7	13
22	Hermansky-Pudlak syndrome and oculocutaneous albinism in Chinese children with pigmentation defects and easy bruising. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 52.	2.7	13
23	Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. <i>Modern Pathology</i> , 2021, 34, 1143-1152.	5.5	12
24	External Quality Assurance of Platelet Function Assays: Results of the College of American Pathologists Proficiency Testing Program. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 472-482.	2.5	11
25	Clinical characteristics and platelet phenotype in a family with RUNX1 mutated thrombocytopenia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1963-1967.	1.3	10
26	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. <i>American Journal of Clinical Pathology</i> , 2021, 156, 679-690.	0.7	10
27	A Case of Hairy Cell Leukemia With CCND1-IGH Translocation. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1080-1084.	3.7	9
28	Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. <i>British Journal of Haematology</i> , 2020, 190, e316-e320.	2.5	9
29	DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. <i>Frontiers in Oncology</i> , 2022, 12, 849376.	2.8	9
30	Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease. <i>Journal of Molecular Biology</i> , 2020, 432, 305-323.	4.2	8
31	Testing for dabigatran and rivaroxaban by clinical laboratories. <i>American Journal of Hematology</i> , 2016, 91, E464-E467.	4.1	7
32	Clinical and laboratory diagnosis of autoimmune factor V inhibitors: A single institutional experience. <i>Thrombosis Research</i> , 2018, 171, 14-21.	1.7	7
33	Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature. <i>Modern Pathology</i> , 2022, 35, 865-874.	5.5	7
34	A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 1127-1134.	4.1	7
35	Not all CALR mutations are created equal. <i>Leukemia and Lymphoma</i> , 2015, 56, 2482-2483.	1.3	6
36	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 46.	6.2	6
38	Grey platelet syndrome misdiagnosed as <scp>ITP</scp>. <i>British Journal of Haematology</i> , 2016, 173, 662-662.	2.5	5
39	Heat inactivation of extended half-life factor VIII concentrates. <i>Haemophilia</i> , 2019, 25, e130-e131.	2.1	5
40	Factor V Deficiency with a Thrombotic Clinical Phenotype. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 108-112.	2.7	5
41	Evaluation of soluble fibrin monomer complex in patients in SARS-CoV-2 COVID-19 infection-associated coagulopathy. <i>European Journal of Haematology</i> , 2022, 108, 319-326.	2.2	5
42	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. <i>British Journal of Haematology</i> , 2018, 182, 141-145.	2.5	4
43	Revisiting the effects of spectral interfering substances in optical endpoint coagulation assays. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1181-1190.	1.3	4
44	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. <i>American Journal of Hematology</i> , 2018, 93, E401-E404.	4.1	3
45	Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. <i>Cancer Genetics</i> , 2020, 241, 67-71.	0.4	3
46	Platelet transfusion: The effects of a fluid warmer on platelet function. <i>Transfusion</i> , 2021, 61, 52-56.	1.6	3
47	Evaluation of Soluble Fibrin Monomer Complex in Patients with Sars-Cov-2 COVID-19 Infection. <i>Blood</i> , 2020, 136, 27-28.	1.4	3
48	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. <i>Blood</i> , 2015, 126, 1050-1050.	1.4	3
49	Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 5234-5234.	1.4	3
50	Indolent Mantle Cell Lymphoma: A Distinct Subgroup Characterized by Leukemic Phase Disease without Lymphadenopathy.. <i>Blood</i> , 2009, 114, 3937-3937.	1.4	3
51	Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease. <i>Blood</i> , 2016, 128, 2275-2275.	1.4	2
52	Factor IX Gene (F9) Genotyping Trends and Spectrum of Mutations Identified: A Reference Laboratory Experience. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 287-292.	2.7	2
53	The Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban: Results of the College of American Pathologists External Quality Assessment Program. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, , .	2.5	1
54	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4560-4560.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. <i>Blood</i> , 2019, 134, 3003-3003.	1.4	1
56	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019, 134, 3863-3863.	1.4	1
57	Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review. <i>Blood</i> , 2020, 136, 25-26.	1.4	1
58	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. <i>Blood Cancer Journal</i> , 2022, 12, 12.	6.2	1
59	Greatly increased giant platelets mimicking blasts in flow cytometric analysis from a patient with primary myelofibrosis. <i>Journal of Hematopathology</i> , 2018, 11, 21-22.	0.4	0
60	An In Silico Exploration of the Factors That Affect the Precision of the Bethesda Assay. <i>American Journal of Clinical Pathology</i> , 2020, 154, 671-682.	0.7	0
61	A novel likely-pathogenic variant in a patient with Hermansky-Pudlak Syndrome. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, mcs.a006110.	1.2	0
62	Charaterization of Human Primitive Megakaryocytes and Platelets. <i>Blood</i> , 2006, 108, 1520-1520.	1.4	0
63	Isolated Trisomy 8 in the Myelodysplastic Syndromes.. <i>Blood</i> , 2009, 114, 2785-2785.	1.4	0
64	GF11B Mutation Associated Alpha-Delta Platelet Storage-Pool Deficiency: A Case Report and Its Potential Important Implication. <i>Blood</i> , 2016, 128, 3727-3727.	1.4	0
65	Identification of a Novel Heterozygous Mutation (c.2213T>G;p.Leu738Arg) in Platelet Glycoprotein ITGB3 gene in a Patient with Glanzmann's Thrombasthenia. <i>Blood</i> , 2018, 132, 1158-1158.	1.4	0
66	Novel Hermansky-Pudlak Syndrome Type 6 Missense Variant Associated with Subclinical Oculocutaneous Albinism and Mild Bleeding. <i>Blood</i> , 2018, 132, 1153-1153.	1.4	0
67	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018, 132, 2689-2689.	1.4	0
68	No Diagnostic Utility of Zero Heparin Control Buffer in Serotonin Release Assay: Findings from a Validation Study. <i>Blood</i> , 2021, 138, 3227-3227.	1.4	0
69	Diagnostic Utility of High Dose Heparin Confirmation Step in Heparin Induced Thrombocytopenia ELISA Assay. <i>Blood</i> , 2021, 138, 3228-3228.	1.4	0
70	Detection of Monoclonal Immunoglobulin By Mass Spectrometry in Patients Evaluated for Thrombotic Microangiopathy (TMA). <i>Blood</i> , 2020, 136, 17-17.	1.4	0
71	Thrombophilia Testing Practices: The Mayo Clinic Experience. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
72	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. <i>Blood</i> , 2020, 136, 34-35.	1.4	0